View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Koya Keizo
(Last) (First) (Middle)
C/O SYNTA PHARMACEUTICALS CORP.
45 HARTWELL AVENUE
(Street)
LEXINGTON MA 02421
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2007 		3. Issuer Name and Ticker or Trading Symbol
SYNTA PHARMACEUTICALS CORP [ SNTA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr. VP, Drug Development
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 33,218(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) (2) 12/13/2012 Common Stock 125,000(3) 10.843(3) D
Employee Stock Option (Right to Buy) (4) 06/17/2013 Common Stock 50,000(3) 10.843(3) D
Employee Stock Option (Right to Buy) (5) 05/27/2014 Common Stock 10,000(3) 14(3) D
Employee Stock Option (Right to Buy) (6) 02/15/2015 Common Stock 17,900(3) 14(3) D
Employee Stock Option (Right to Buy) (7) 02/15/2016 Common Stock 26,785(3) 14(3) D
Explanation of Responses:
1. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which the number of shares of Common Stock was divided by 4.
2. The option vested as to 37,500 shares on October 1, 2002 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter and is currently fully vested.
3. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of Common Stock underlying the option was divided by 4 and (ii) the exercise price of the option was multiplied by 4.
4. The option vested as to 25% of the shares on April 1, 2004 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter.
5. The option vested as to 25% of the shares on March 1, 2005 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter.
6. The option vested as to 25% of the shares on February 15, 2006 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter.
7. The option vests as to 25% of the shares on February 15, 2007 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter.
/s/ Ann Margaret Eames, Attorney-in-Fact 02/05/2007
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

	Know all by these presents, that the undersigned
hereby constitutes and appoints each of Safi R. Bahcall,
Ph.D., the President and Chief Executive Officer of Synta
Pharmaceuticals Corp. (the "Company"), Keith S. Ehrlich,
the Vice President, Finance and Administration, Chief
Financial Officer of the Company, and Wendy E. Rieder,
the Vice President, Intellectual Property and Legal
Affairs, General Counsel of the Company, and Brian Keane,
Daniel T. Kajunski, and Ann Margaret Eames of Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing
singly, with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer, director
			and/or 10% shareholder of the Company,
forms and authentication documents for EDGAR Filing
		Access;

	(2)	do and perform any and all acts for and on
behalf of the undersigned which may be necessary or
		desirable to complete and execute any such
forms and authentication documents;

	(3)	execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer,
director and/or 10% shareholder of the
Company, Forms 3, 4 and 5 in accordance with
Section 16(a) of the Securities Exchange Act
of 1934 and the rules thereunder;

	(4)	do and perform any and all acts for and on
behalf of the undersigned which may be
necessary or desirable to complete and
execute any such Form 3, 4 or 5 and timely
file such form with the United States
Securities and Exchange Commission and any
stock exchange or similar authority; and

	(5)	take any other action of any type whatsoever
in connection with the foregoing which, in
the opinion of such attorney-in-fact, may be
of benefit to, in the best interests of, or
legally required by the undersigned, it being
understood that the documents executed by
such attorney-in-fact on behalf of the
undersigned pursuant to this Power of
Attorney shall be in such form and shall
contain such terms and conditions as such
attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such
attorney-in-fact full power and authority to do and
perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do
if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and
powers herein granted.  The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16
of the Securities Exchange Act of 1934, as amended.

	This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to
file Forms 3, 4 and 5 with respect to the undersigned's
holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a
signed writing delivered to the foregoing attorneys-in-
fact.

	IN WITNESS WHEREOF, the undersigned has caused this
Power of Attorney to be executed this 29th day of January
2007.



/s/ Keizo Koya
Signature


Keizo Koya
Print Name